Game-changing obesity drugs go mainstream:

what scientists are learning

June 22, 2023

Phenomix Sciences's Co-Founder Dr. Andres Acosta's, M.D., Ph.D., findings and unique approach to obesity treatment were recognized in a recent article from Nature Journal. The article, "Game-changing obesity drugs go mainstream: what scientists are learning," outlines the research to tackle who's most likely to lose weight on the new generation of anti-obesity medications.

Everybody wants to try (Ozempic and Wegovy) but not everyone responds to them." Dr. Acosta dives into his decades of phenotyping research and how people's response to these GLP-1s depend on the underlying cause of their obesity or phenotype.  He discusses the initial four phenotypes we have identified and how they can be used to build a personalized treatment plan for obesity patients.

Nature subscribers can read the full article here: https://www.nature.com/articles/d41586-023-01712-8

To learn more about Phenomix Sciences, click here.